CC-90002, a newer CD47 antagonist, demonstrated potential efficacy in preclinical models but a phase I study for R/R AML and MDS was terminated due to lack of monotherapy activity and evidence of anti-drug antibodies (68–70). Here, CD47 is linked to acute myeloid leukemia.